Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

About this update from Stoke Therapeutics, Inc.

–Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scientific discoveries into new medicines for people with severe diseases– BEDFORD, Mass., July 13, 2026 --( BUSINESS WIRE )-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Thomas McCauley, Ph.D., has been appointed Chief Scientific Officer. Dr. McCauley joins Stoke with more than 25 years of experience leading high-performing R&D teams and translating early scientific discoveries into clinical programs that have delivered new medicines to people living with severe diseases. He brings extensive expertise in developing novel technology platforms and modalities across multiple therapeutic areas, including six years at Shire where he played a key role in the late-stage development and global approvals of multiple genetic medicines for rare diseases. In this new role, he will be responsible for leading Stoke's scientific strategy and leveraging the Company's proprietary RNA medicines platform to expand and advance its pipeline. "Our first investigational medicine, zorevunersen, has shown the potential to change the course of Dravet syndrome by addressing the underlying genetic cause of the disease," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "As we build on this proof-of-concept for our platform and expand our pipeline beyond Dravet, Tom's leadership and deep translational expertise will help us identify and advance the best opportunities to turn novel science from our research organization into more life-changing medicines for patients." "Throughout my career, I have had the opportunity to drive the development of medicines across a wide range of modalities and scientific platforms. Stoke's approach of upregulating protein expression stood out to me for its potential to transform the way many severe genetic diseases are treated," said Dr. McCauley. "I am very impressed and energized by the progress the team has already made, including advancing a potential first-in-class disease-modifying medicine for Dravet syndrome from early research into late-stage development. I look forward to partnering with Stoke's co-founder and Chief Technology Officer Isabel Aznarez and the broader organization to build on that foundation and help realize the full potential of this promising scientific approach."

View stock analysis, news, and events for Stoke Therapeutics, Inc.